Consensus Cencora, Inc. Berne S.E.

Stocks

ABG

US03073E1055

Medical Equipment, Supplies & Distribution

End-of-day quote Berne S.E. 22/07/2026			5-day change	1st Jan Change
242.59 ^CHF	-1.39%		-.--%	-1.93%

09-15	Cencora, Inc. Presents at 2026 Global Healthcare Conference, Sep-15-2026 03:10 PM
09-15	Cencora, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 08:30 AM

edbd14016c40b62ee9ca1bb2295d3345.nwGqIZdBMMNNI8z36wm0i8V95Gi3ayI4KqQ8iu-3W14.5kjPGe0XaKoMQp_GoVHM8ZYZljnYCHFIQ_Bf5qnSDhvsbeV2oQlIuzRa_A~a0215714a32aaa6101a8a16be9e6219a

Analysts' recommendations: Cencora, Inc.

08-19	RBC Initiates Cencora at Sector Perform With $330 Price Target	MT
08-11	Wells Fargo Adjusts Price Target on Cencora to $395 From $331, Keeps Overweight Rating	MT
08-07	JPMorgan Adjusts Price Target on Cencora to $390 From $382	MT
08-06	Citigroup Adjusts Price Target on Cencora to $370 From $355	MT
08-06	Leerink Partners Adjusts Price Target on Cencora to $380 From $368	MT
08-06	Evercore ISI Adjusts Price Target on Cencora to $350 From $330	MT
08-06	Baird Adjusts Price Target on Cencora to $370 From $340	MT
08-06	UBS Adjusts Price Target on Cencora to $430 From $412, Maintains Buy Rating	MT
07-22	Baird Adjusts Price Target on Cencora to $340 From $337, Maintains Outperform Rating	MT
07-21	BofA Securities Adjusts Cencora Price Target to $310 From $285	MT
07-07	Evercore ISI Adjusts Price Target on Cencora to $330 From $300	MT
06-24	Argus Adjusts Price Target on Cencora to $340 From $4000, Maintains Buy Rating	MT
06-24	BofA Adjusts Price Target on Cencora to $285 From $280	MT
06-10	Barclays Cuts Cencora Price Target to $350 From $425, Maintains Overweight Rating	MT
05-21	Baird Adjusts Price Target on Cencora to $337 From $339, Maintains Outperform Rating	MT
05-11	Wells Fargo Adjusts Price Target on Cencora to $331 From $429	MT
05-08	McKesson's Fiscal 2027 Guidance 'Encouraging,' Cencora Selloff Overdone, Morgan Stanley Says	MT
05-08	Morgan Stanley Lowers Price Target on Cencora to $342 From $400, Keeps Overweight Rating	MT
05-07	UBS Adjusts Price Target on Cencora to $412 From $410, Maintains Buy Rating	MT
04-28	William Blair Initiates Cencora at Market Perform	MT
04-08	Evercore ISI Adjusts Price Target on Cencora to $360 From $420, Maintains Outperform Rating	MT
03-19	Baird Adjusts Price Target on Cencora to $420 From $415, Maintains Outperform Rating	MT
03-02	Leerink Partners Adjusts Price Target on Cencora to $447 From $410, Maintains Outperform Rating	MT
02-13	Barclays Adjusts Cencora Price Target to $425 From $400, Maintains Overweight Rating	MT
02-10	Wells Fargo Adjusts Price Target on Cencora to $429 From $405, Maintains Overweight Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBOTT LABORATORIES					+17.64%
	MEDTRONIC PLC					+13%
	CENCORA, INC.					+19.36%
	BECTON, DICKINSON AND COMPANY					+7.88%
	HOYA CORPORATION					+33.01%
	DEXCOM, INC.					+7.45%
	MEDLINE INC.					+38.85%
	WEST PHARMACEUTICAL SERVICES, INC.					+10.58%
	SARTORIUS STEDIM BIOTECH					+20.09%
	Average					+18.65%
	Weighted average by Cap.					+17.55%